|
|
 |
|
Viewing report
|
|
|
|
Success Rates in Biotech - Going The Wrong Way
Avance, March 2009, Pages: 38
The report 'Success Rates in Biotech - Going The Wrong Way' summarises our review of 211 public biotech companies comprising over 1,500 drug development projects. We have studied the clinical pipelines going back to 2002 based on financial reports and found a striking difference of success probabilities compared to data derived form pharmaceutical companies.
In the report, the success rates resulting from the analysis are discussed, especially in view of their implications to the management of biotech firms and investments in these companies.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Multiplexed Diagnostics 2010 Market Report
Biomarkers - Technologies, Markets and Companies
Cell Therapy - Technologies, Markets and Companies
Gene Therapy - Technologies, Markets and Companies
Personalized Medicine: Companies, Trends and World Market
Nanobiotechnology Applications, Markets and Companies
RNAi - Technologies, Markets and Companies
Genetic Engineering - Global Outlook
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Bio/Pharma R&D Statistical Sourcebook 2010/2011
|
|
|
|
